S E C U R I T I E S A N D E X C H A N G E
C O M M I S S I O N
Washington, D. C. 20549
F O R M 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 28, 1996
T H E L I P O S O M E C O M P A N Y, I N C.
(Exact name of registrant as specified in its charter)
Delaware 0-14887 22-2370691
(State or other juris- (Commission File No) (I.R.S. Employer
diciton of incorpora- Identification No.)
One Research Way, Princeton Forrestal Center, Princeton,
New Jersey, 08540
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:(609) 452-7060
None
(Former name or former address, if changed since last report.)
Item 5. Other Events.
On February 28, 1996, The Liposome Company, Inc. (the "Company") released a
press release, a copy of which is attached hereto as Exhibit 20 with respect to
the Company's sales of ABELCETTM (Amphotericin B Lipid Complex Injection).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE LIPOSOME COMPANY, INC.
Dated: February 29, 1996 By: /s/ Brooks Boveroux
Brooks Boveroux
Vice President, Finance,
Chief Financial Officer
and Treasurer
EXHIBIT INDEX
Exhibit Page No.
20 - Copy of the Company's press release of February 28, 1996 5
relating to the Company's sales of ABELCETTM (Amphotericin
B Lipid Complex Injection).
Exhibit 20
THE LIPOSOME COMPANY, INC. REPORTS
MORE THAN $6 MILLION IN SALES OF ABELCETTM
IN THE FIRST 8 WEEKS OF 1996
Princeton, NJ -- February 28, 1996 --The Liposome Company, Inc. (Nasdaq: LIPO
and LIPOZ) is concerned about inaccurate information in the investment community
concerning ABELCETTM and its sales prospects. To correct any misperceptions,
the Company is announcing that the 1996 year-to-date sales of ABELCETTM in the
U.S. and overseas have been more than $6 million.
"The launch of ABELCETTM has been extremely well received by physicians in the
U.S.," said Charles A. Baker, Chairman and Chief Executive Officer. "To date,
we have sold ABELCETTM into about 80% of the 50 hospitals that are the largest
users of amphotericin B."
The Liposome Company, Inc. is a leading biotechnology company dedicated to the
development and commercialization of proprietary lipid and liposome-based
pharmaceuticals for the treatment, prevention and diagnosis of inadequately
treated, life-threatening diseases, such as ABELCETTM for severe systemic
fungal infections, TLC D-99 for metastatic breast cancer, and TLC C-53 for
acute respiratory distress syndrome. ABELCETTM (Amphotericin B Lipid Complex
Injection) is approved for marketing in the United States, United Kingdom,
Spain, Luxembourg and Iceland.
